Nasdaq · Common Stock · Biological Products, (No Diagnostic Substances)
American multinational biotechnology company
84 entities across 38 jurisdictions, 3 in offshore financial centres. Read directly from the company’s own 10-K EX-21 filed 2026-02-06 — see the exhibit.
Which other public companies file entities in the same places:
| Entity | Jurisdiction | Note |
|---|---|---|
| Biogen Foundation Inc. | Massachusetts | |
| Biogen MA Inc. | Massachusetts | |
| Biogen Realty Corporation | Massachusetts | |
| Biogen Realty Limited Partnership | Massachusetts | |
| Biogen U.S. Corporation | Massachusetts | |
| Biogen U.S. Limited Partnership | Massachusetts | |
| Alcyone Therapeutics, Inc. | Delaware | |
| Biogen (RTP) Realty LLC | Delaware | |
| Biogen Chesapeake LLC | Delaware | |
| Biogen Digital Health Inc. | Delaware | |
| Biogen Digital Health Global LLC | Delaware | |
| Biogen Holding I LLC | Delaware | |
| Biogen Holding II LLC | Delaware | |
| Biogen OUS Holding Inc. | Delaware | |
| Biogen Manufacturing Holding LLC | Delaware | |
| Biogen New Ventures Inc. | Delaware | |
| Biogen SRO Inc. | Delaware | |
| Biogen Therapeutics Inc. | Delaware | |
| Biogen U.S. Pacific LLC | Delaware | |
| Biogen U.S. West Corporation | Delaware | |
| Conforma Therapeutics Corporation | Delaware | |
| Human Immunology Biosciences, Inc. | Delaware | |
| Stromedix, LLC | Delaware | |
| Nightstar, Inc. | Delaware | |
| Reata Pharmaceuticals Global, Inc. | Delaware | |
| Reata Pharmaceuticals Holdings, LLC. | Delaware | |
| Reata Pharmaceuticals, Inc. | Delaware | |
| Biogen (Argentina) SRL | Argentina | |
| Biogen Australia PTY Ltd | Australia | |
| Biogen Austria GmbH | Austria | |
| Biogen Belgium N.V./S.A. | Belgium | |
| Biogen International Holding Limited | Bermuda | offshore centre |
| Biogen (Bermuda) Technologies Ltd. | Bermuda | offshore centre |
| Biogen Brasil Produtos Farmaceuticos LTDA | Brazil | |
| Biogen Canada Inc. | Canada | |
| Biogen Chile SpA | Chile | |
| Biogen Biotechnology (Shanghai) Co., Ltd | China | |
| BIIB Colombia S.A.S. | Colombia | |
| Biogen (Czech Republic) s.r.o. | Czech Republic | |
| Biogen (Denmark) A/S | Denmark | |
| Biogen Finland OY | Finland | |
| Biogen France S.A.S. | France | |
| Biogen GmbH | Germany | |
| Reata Germany GmbH | Germany | |
| Biogen Hong Kong Limited | Hong Kong | |
| Biogen Hungary KFT | Hungary | |
| Biogen Idec Biotech India Pvt. Ltd. | India | |
| Biogen Capability Center India Private Limited | India | |
| Biogen Idec (Ireland) Ltd. | Ireland | |
| Nightstar Europa Limited | Ireland | |
| Biogen Distribution Services Limited | Ireland | |
| Biogen Italia S.R.L. | Italy | |
| Biogen Japan Ltd. | Japan | |
| Biogen Korea LLC | Korea | |
| Biogen Luxembourg Holding S.a.r.l. | Luxembourg | offshore centre |
| Biogen Mexico S. de R.L. de C.V. | Mexico | |
| Biogen NZ Biopharma Ltd. | New Zealand | |
| Biogen Norway AS | Norway | |
| Biogen Poland Sp. z.o.o. | Poland | |
| Biogen Portugal Sociedade Farmaceutica, Unipessoal Lda. | Portugal | |
| Biogen Arabia Limited | Saudi Arabia | |
| Biogen Regional Headquarters LLC | Saudi Arabia | |
| Biogen Spain, S.L. | Spain | |
| Biogen Sweden AB | Sweden | |
| Biogen Digital Health International GmbH | Switzerland | |
| Biogen International GmbH | Switzerland | |
| Biogen International Neuroscience GmbH | Switzerland | |
| Biogen Management Services GmbH | Switzerland | |
| Biogen Switzerland AG | Switzerland | |
| Eidetica Biopharma GmbH | Switzerland | |
| Biogen Taiwan Limited | Taiwan | |
| Biogen Turkey Ilac Ticaret Limited Sirketi | Turkey | |
| Biogen B.V. | The Netherlands | |
| Biogen Netherlands B.V. | The Netherlands | |
| Biogen Idec Limited | United Kingdom | |
| Biogen Idec Research Ltd. | United Kingdom | |
| Convergence Pharmaceuticals Limited | United Kingdom | |
| Convergence Pharmaceuticals Holdings Ltd. | United Kingdom | |
| Old Convergence Pharmaceuticals Limited | United Kingdom | |
| Reata U.K. Limited | United Kingdom | |
| Silver Acquisition Co. Ltd. | United Kingdom | |
| Nightstar Therapeutics Limited | United Kingdom | |
| NightstaRx Limited | United Kingdom | |
| Tungsten Bidco Limited | United Kingdom |
Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
| Year | Revenue | Net income | Free cash flow | Gross margin | Shares |
|---|---|---|---|---|---|
| FY2020 | $13.4B | $4.0B | $3.8B | 86.6% | 161,300,000 |
| FY2021 | $11.0B | $1.6B | $3.4B | — | 149,600,000 |
| FY2022 | $10.2B | $3.0B | $1.1B | — | 146,000,000 |
| FY2023 | $9.8B | $1.2B | $1.3B | — | 145,600,000 |
| FY2024 | $9.7B | $1.6B | $2.7B | — | 145,900,000 |
| FY2025 | $9.9B | $1.3B | $2.1B | — | 147,100,000 |
14 institutions tracked — 9 added, 4 reduced, 1 opened a new position.
| Manager | Kind | Shares | Change | Value |
|---|---|---|---|---|
| FMR LLC | Active fund | 18,217,239 | +5,409,698 | $3.9B |
| Point72 Asset Management, L.P. | Hedge fund | 88,749 | −725,568 | $19.2M |
| CITADEL ADVISORS LLC | Hedge fund | 867,556 | +336,863 | $187.4M |
| MORGAN STANLEY | Active fund | 2,411,271 | +240,331 | $521.0M |
| JPMORGAN CHASE & CO | Active fund | 1,823,140 | −211,869 | $394.9M |
| STATE STREET CORP | Index | 7,344,327 | +176,405 | $1.6B |
| WELLINGTON MANAGEMENT GROUP LLP | Active fund | 3,117,469 | +155,828 | $673.6M |
| RENAISSANCE TECHNOLOGIES LLC | Hedge fund | 77,744 | −125,652 | $16.8M |
| GEODE CAPITAL MANAGEMENT, LLC | Index | 4,449,295 | +106,693 | $957.9M |
| PRICE T ROWE ASSOCIATES INC /MD/ | Active fund | 774,283 | +101,856 | $167.3M |
| BANK OF AMERICA CORP /DE/ | Active fund | 1,116,228 | −40,141 | $241.2M |
| AQR CAPITAL MANAGEMENT LLC | Hedge fund | 1,936,859 | +13,302 | $416.9M |
| BlackRock, Inc. | Index | 15,985,736 | +11,135 | $3.5B |
NORGES BANK holds a position with no prior filing to compare against, so its change is unknown rather than zero — and it is left out of the totals above.
From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register.
Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.
BIOGEN INC. files under SIC 2836 — all 11 biological products, (no diagnostic substances) companies compared on assets and F-score.
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.
